This study optimized a dPCR assay for the detection of mutations in plasma collected from metastatic breast cancer patients by comparing mutation detection and variant allele frequency obtained using single-locus versus multiplex pre-amplification, and different volumes of plasma and cfDNA as input. Mutational profiles from dPCR analysis and next-generation sequencing were compared as were those from longitudinal specimens. Blood for this study had been previously collected from 156 patients diagnosed with metastatic breast cancer (95 patients had received endocrine therapy and 43 patients had received chemotherapy) and ten healthy blood donors. Blood was collected in Vacutainer EDTA tubes. Additionally, 2- 5 longitudinal specimens were collected from 17 patients. Blood was transported at ambient temperature, and plasma and circulating tumor cells (CTC) were separated within 24 h of venipuncture. Plasma was separated by centrifugation at 1711 g for 10 min and stored at -80°C. Before thawing, 5 mmol/L dithiothreitol was added to plasma specimens. Plasma was centrifuged a second time at 12,000 g for 10 min at 4°C before cfDNA isolation from 200 µL plasma using the QIAamp Circulating Nucleic Acid Kit with 20 µL elution buffer applied to the column three times. cfDNA was quantified using the Qubit dsDNA HS Assay Kit and stored at -30°C for < 1 week or at -80°C. cfDNA was preamplified using a TaqMan PreAmp Kit and either a single locus-specific (ESR1) approach or a multiple loci (ESR1, BRAF, KRAS, PIK3CA, and TP53) approach. Samples were then amplified using hotspot mutation-specific assays and the QuantStudio 3D Digital PCR System. A total of 152 different mutations were sequenced in specimens from 17 breast cancer patients and ten healthy volunteers using the Ion Torrent Oncomine Breast cfDNA Assay on an Ion Torrent S5XL NGS system a range of DNA inputs (<1 to 10.41 ng DNA). A comparison of different plasma volumes was conducted by extracting DNA from plasma spiked with D538G ESR1.